{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-254476","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-03T10:01:45+00:00","discovered_at":"2026-06-03T10:10:00.257454+00:00","generated_at":"2026-06-03T10:12:00.107827+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IDEAYA announces clinical collaboration with Roche for PRMT5 + pan-RAS combo in MTAP-deleted PDAC","bullets":["IDE892 (PRMT5 inhibitor) to be combined with Roche's RG6505 (pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic cancer.","IDEAYA will sponsor the Phase 1 combination trial; Roche will supply RG6505.","MTAP deletion occurs in up to 40% of PDAC; almost all such cases have co-occurring RAS mutations.","Both companies retain full commercial rights to their compounds; joint governance oversees the study.","Triplet combination with IDE397 (MAT2A inhibitor) may be evaluated with joint approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-254476","json":"https://secwatch.observer/filing/0001193125-26-254476.json","markdown":"https://secwatch.observer/filing/0001193125-26-254476.md","text":"https://secwatch.observer/filing/0001193125-26-254476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526254476/0001193125-26-254476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526254476/d53214d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T10:12:00.107827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}